SCHEMBL25857265

SCHEMBL25857265

C[N+](C)(C)CCOP(=O)(O)OCC[N+](C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.46
LMNA P02545 3/20 0.46
ADRA1A P35348 2/20 0.46
FABP3 P05413 1/20 0.46
ESR1 P03372 1/20 0.46
ADORA3 P0DMS8 1/20 0.46
CDC25A P30304 1/20 0.46
AGTR1 P30556 1/20 0.46
AKT1 P31749 1/20 0.46
KCNH2 Q12809 1/20 0.46
CHRM5 P08912 6/20 0.44
CHRM1 P11229 6/20 0.44
CHRM3 P20309 6/20 0.44
CHRM2 P08172 5/20 0.44
CHRM4 P08173 5/20 0.44
CHRNB2 P17787 4/20 0.44
CHRNA4 P43681 4/20 0.44
CHRNA7 P36544 3/20 0.44
BBOX1 O75936 2/20 0.44
HTR1A P08908 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13745842 0.93 FABP3 (0.43) SMN1; SMN2LMNAADRA1AFABP3ESR1
SCHEMBL26556572 0.91 FABP3 (0.42) SMN1; SMN2LMNAADRA1AFABP3ESR1
SCHEMBL1692413 0.91 LMNA (0.49) SMN1; SMN2LMNAADRA1AFABP3ESR1
SCHEMBL17833014 0.91 LMNA (0.58) SMN1; SMN2LMNAADRA1AFABP3ESR1
SCHEMBL192297 0.91 FABP3 (0.45) SMN1; SMN2LMNAADRA1AFABP3ESR1
SCHEMBL16638189 0.91 SMN1; SMN2 (0.49) SMN1; SMN2LMNAADRA1AFABP3ESR1
SCHEMBL13978765 0.91 FABP3 (0.42) SMN1; SMN2LMNAADRA1AFABP3ESR1
SCHEMBL13123029 0.91 SMN1; SMN2 (0.45) SMN1; SMN2LMNAADRA1AFABP3ESR1
SCHEMBL13619237 0.91 LMNA (0.58) SMN1; SMN2LMNAADRA1AFABP3ESR1
SCHEMBL15778356 0.91 SMN1; SMN2 (0.43) SMN1; SMN2LMNAADRA1AFABP3ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230330650-A1 MOLECULAR SIEVES WITH INTERGROWN PHASES OF AEI AND CHA TOPOLOGIES AND CATALYST THEREOF CHINA AUTOMOTIVE TECHNOLOGY AND RESEARCH CENTER CO., LTD (CN) 2023-10-19 US disclosed
CN-114938650-B Polyurethane or polyurethane urea, antithrombotic coating agent, antithrombotic medical device, and method for producing same 第一工业制药株式会社 2023-09-26 CN disclosed
WO-2023130745-A1 AEI-CHA SYMBIOTIC MOLECULAR SIEVE AND CATALYST THEREOF 中汽研汽车检验中心(天津)有限公司 2023-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230330650-A1 MOLECULAR SIEVES WITH INTERGROWN PHASES OF AEI AND CHA TOPOLOGIES AND CATALYST THEREOF HAO2, SOST, HAO1 SMN1; SMN2 4370/4885LMNA 4173/4885ADRA1A 3774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.